

1 **Effectiveness of Ferritin-guided Donation Intervals in Blood Donors: Results of the Stepped-wedge**

2 **Cluster Randomised FIND'EM Trial**

3 Amber Meulenbeld^{1,2}, a.meulenbeld@sanquin.nl

4 Steven Ramondt^{1,3}, s.ramondt@vu.nl

5 Maike G. Sweegers¹, m.sweegers@nki.nl

6 Franke A. Quee^{1,2}, f.quee@sanquin.nl

7 Femmeke J. Prinsze¹, f.prinsze@sanquin.nl

8 Emiel O. Hoogendijk^{4,5}, e.hoogendijk@amsterdamumc.nl

9 Dorine W. Swinkels^{6,7}, dorine.swinkels@radboudumc.nl

10 Katja van den Hurk^{1,2}, k.vandenhurk@sanquin.nl

11 1. Donor Studies, Donor Medicine Research, Sanquin Research, Amsterdam, the Netherlands;

12 2. Department of Public and Occupational Health, Amsterdam Public Health research institute,
13 Amsterdam UMC, Amsterdam, the Netherlands;

14 3. Department of Communication Science, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands;

15 4. Department of Epidemiology and Data Science, Amsterdam Public Health research institute,
16 Amsterdam UMC, Amsterdam, the Netherlands;

17 5. Department of General Practice, Amsterdam Public Health research institute, Amsterdam UMC –
18 Location VU University medical centre, Amsterdam, the Netherlands;

19 6. Department of Laboratory Medicine, Radboud University Nijmegen, Nijmegen, Gelderland, The
20 Netherlands;

21 7. Centre for Iron Disorders Sanquin, Sanquin Blood Supply Foundation, Amsterdam, Noord-Holland, The
22 Netherlands.

23

24 **Running head:** FIND'EM: A stepped-wedge trial of ferritin monitoring in blood donors

25 **Words (max 2500):** 2993
This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Corresponding author**

27 Amber Meulenbeld

28 Sanquin Research

29 Plesmanlaan 125

30 PO box 9137

31 1006 AC Amsterdam, the Netherlands

32 E-mail: a.meulenbeld@sanquin.nl

33 **Abstract**

34 **Background**

35 Whole blood donors are at increased risk for iron deficiency and anaemia. The current standard of
36 haemoglobin (Hb) monitoring is insufficient to ensure the maintenance of proper iron reserves and
37 donor health. We determine the effects of ferritin-guided donation intervals for blood donors and the
38 blood supply.

39 **Methods**

40 A ferritin-guided donation interval policy was implemented and evaluated through a stepped-wedge
41 cluster-randomised controlled trial in all blood collection centres in the Netherlands. Ferritin was
42 measured in new donors and at every 5th donation. Subsequent donation intervals were extended to
43 six months if ferritin was 15 - 30 ng/mL and to twelve months if ferritin was <15 ng/mL. Primary
44 outcomes are ferritin and Hb levels, iron deficiency, Hb deferral, and donor return. Secondary
45 outcomes are self-reported iron deficiency-related symptoms. Operational statistics assessed the
46 impact on the blood supply.

47 **Findings**

48 Among 412,888 whole blood donors, 36,099 were measured. Ferritin-guided intervals increased
49 ferritin levels by 0.24 log₁₀ ng/mL (95% CI 0.22 – 0.27, p <0.001) and Hb by 0.37 g/dL (95% CI 0.31 –
50 0.43, p <0.001). Donors were less likely to be iron deficient (OR 0.15, 95% CI 0.10 – 0.21, p <0.001) or
51 deferred based on Hb (OR 0.23, 95% CI 0.11 – 0.41, p <0.001). However, donors returned less
52 frequently (OR 0.60, 95% CI 0.51 – 0.67, p <0.001), necessitating more invitations and reducing the
53 average donation frequency. No improvement in self-reported symptoms was observed.

54 **Interpretation**

55 Ferritin-guided donation intervals significantly improved Hb and ferritin levels, reducing iron
56 deficiency and Hb deferrals. While beneficial for iron and Hb maintenance, efforts are needed to
57 recruit and retain donors and remedy self-reported symptoms.

58 **Funding and registration**

59 This project received support from the 'Product and Process Development Cellular Products Grant'
60 (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee of Sanquin. The
61 trial was registered in the Dutch trial registry (NTR6738) on September 29th, 2017
62 (<https://trialssearch.who.int/Trial2.aspx?TrialID=NTR6738>).

63

64 Key words: blood donation, donation interval, donor health, stepped-wedge cluster randomised trial,
65 ferritin

66 **Introduction**

67 Annually, more than 100 million whole blood donations are made worldwide to provide life-saving
68 treatment for patients requiring transfusion. Whole blood donors that donate repeatedly are at risk
69 of developing iron deficiency and subsequent iron deficiency anaemia (1). Iron deficiency also has
70 effects beyond that of anaemia since iron is also found in cytochromes and myoglobin. Male donors
71 lose approximately 8% of their total iron stores with each whole blood donation, whereas
72 menstruating women lose on average 81% of their total iron stores (2–4). Iron stores can be
73 monitored through measuring ferritin. Iron deficiency, ferritin levels <15 ng/ml, presents in
74 approximately 15.0% of female and 9.4% of male Dutch repeat donors (5).

75
76 There is no consensus on iron management strategies for donor health, but key approaches include
77 extended donation intervals and iron supplementation (6–8). Iron supplementation has been reported
78 to reduce fatigue and benefit exercise performance in iron deficient females (9–11). Concerns about
79 negative perceptions, side effects, and low compliance may favour extended donation intervals over
80 iron supplementation (8,12). In previous studies, extended donation intervals were associated with
81 lower risk of haemoglobin (Hb) deferrals (13,14). The INTERVAL trial showed that longer donation
82 intervals led to significantly higher Hb and ferritin levels (14). Most blood establishments monitor Hb
83 to protect donor health, prevent anaemia and ensure sufficient Hb content in the product, deferring
84 blood donors with Hb levels below 13.5 g/dL (males) or 12.5 g/dL (females) (6–8,15,16). However, iron
85 deficiency can present without anaemia, especially in repeat donors (17). As Hb levels may be within
86 acceptable ranges in the presence of iron deficiency, the current standard is insufficient to maintain
87 proper iron reserves (9). The World Health Organization (WHO) advises additional monitoring of
88 ferritin to detect iron deficiency and monitor donor health.

89
90 In 2017, Sanquin Blood Bank in The Netherlands implemented a nationwide policy for iron monitoring
91 of whole blood donors. In addition to Hb monitoring, ferritin is measured at the first visit of new donors

92 and after every fifth whole blood donation of repeat donors (18). If ferritin is between 15 and 30 or
93 below 15 ng/mL, the subsequent donation interval is extended to six or twelve months, respectively
94 (18). A stepped-wedge approach was used to evaluate the effects of this ferritin-guided donation
95 interval policy for whole blood donors on (1) Hb and ferritin levels, (2) iron deficiency, (3) Hb deferral,
96 (4) donor return rates, (5) self-reported iron deficiency-related symptoms, and (6) the blood supply.

97

98 **Methods**

99 *Design*

100 Ferritin measurement IN Donors—Effectiveness of iron Monitoring (FIND’EM) is a stepped-wedge
101 cluster randomised trial, described in detail by Sweegers et al. (18). We conducted cross-sectional
102 ferritin measurements for all donors visiting a blood collection centre during pre-selected weeks
103 before, during, and after implementing a new policy. We measured ferritin in stored plasma samples
104 from donors who consented to use their leftover materials for medical research. Additionally,
105 optional questionnaires were offered to donors. The trial was powered on 4ng/mL change in the
106 ferritin level outcome over six months, assuming a SD of 54 ng/mL, ICC of 0.10 and 150 visits per
107 donation centre (18). The policy and implementation strategy were approved by Sanquin’s Medical
108 and Ethical Advisory Board. The trial was approved by Sanquin’s Board of Directors.

109

110 *Randomization*

111 The 138 fixed and mobile blood collection centres in the Netherlands are divided over 29 staffing
112 clusters that we randomly assigned to four randomization groups. The stepped-wedge design
113 involved random and sequential rollout of ferritin-guided donation intervals by randomization group
114 from November 2017 to November 2019. The allocation was not concealed and the timing of the
115 rollout was revealed before the study. Donors were notified of the new policy through mail upon
116 implementation at their regular donation centre.

117

118 *Procedures*

119 As part of routine procedures, donors undergo a health screening to assess their eligibility to donate
120 by measuring Hb levels and blood pressure and assessing recent travel, sexual and medical history
121 prior to every donation. In the Netherlands, donors also make a screening visit prior to their first
122 donation. In accordance with European legislation, Hb cut-offs for donor eligibility are >13.5 g/dL for
123 males and >12.5 g/dL for females. Donors with low Hb (capillary measurement prior to donation with
124 HemoCue 201, Angelholm, Sweden) are deferred for 3 months. If eligible, males can donate every 56
125 days up to five times a year, females every 122 days up to three times a year, independent of
126 menopausal status.

127

128 The intervention entails extended donation intervals based on ferritin measurements. The cut-offs for
129 extended intervals were based on definitions for iron deficiency (<15 ng/mL, 12 months deferral) and
130 reduced iron levels (≤30 ng/mL, 6 months deferral) by Alvarez-Ossorio et al. (8). The six month interval
131 is based on the results from Schotten et al., suggesting intervals of at least 180 days are required to
132 fully replete iron stores after donation (7). A twelve-month interval is indicated for iron deficient
133 donors to replete to higher levels than pre-donation. In whole blood donors, ferritin is measured at
134 the pre-donation screening visit before the first donation and of each fifth whole blood donation. If
135 ferritin levels are >30 ng/mL, donors are eligible to donate at regular donation intervals. If ferritin levels
136 are ≤30 ng/mL but ≥15 ng/mL, repeat donors are deferred for six months; new donors are allowed to
137 donate, but ferritin is measured again at this first donation, after which they follow the repeat donor
138 policy (18). If ferritin levels are <15 ng/mL, new and repeat donors are deferred from donating for
139 twelve months. Ferritin levels are measured again in the donation after this extended interval. Donor
140 physicians may additionally advise donors to visit their general practitioner and/or donate at a lower
141 frequency (18).

142

143 *Outcome assessment*

144 Before the trial, we established four measurement weeks: 1) one week before implementation
145 (baseline), 2) midway through implementation, 3) one week after full implementation, and 4) one year
146 after full implementation of ferritin-guided donation intervals. Primary outcomes included Hb and
147 ferritin levels, Hb deferral, iron deficiency, and donor return rates, while secondary outcomes included
148 iron deficiency-related symptoms and the impact on the blood supply. Pseudonymized data on age,
149 sex, Hb levels, and deferrals were extracted from the blood bank database (eProgesa software
150 application; MAK-SYSTEM, Paris, France) for donors who visited a blood collection centre during a
151 measurement week and consented to their leftover materials being used for research. Donor return
152 was defined as attempting a donation within six months after becoming eligible to donate again,
153 accounting for minimum donation intervals and possible deferrals. We measured ferritin levels on the
154 Architect i2000sr (Abbott Diagnostics) in plasma samples collected at donation in K3EDTA tubes
155 (VACUETTE®, Greiner Bio-One, Kremsmünster, Austria) and stored at -30°C for three to 24 months (19).
156 The ferritin assay used is traceable to the first WHO Human Liver Ferritin International Standard
157 (80/602). Between-day precision (CV%) of the ferritin assay is 4.1% (95% CI 3.8-4.3%) and constant
158 over a concentration range of 10-500 ng/mL.

159

160 New and repeat donors in fixed blood collection centres during measurement week 2 and 3 that
161 provided informed consent were asked to complete questionnaires. These questionnaires assess
162 physical and mental wellbeing (SF-36), fatigue (Checklist Individual Strength), donation-related
163 symptoms, restless legs syndrome (RLS) and pica, cognitive functioning (Cognitive Failure
164 Questionnaire), and warm glow.(18,20–23) Questionnaires were completed using Qualtrics XM®
165 software (Provo, UT, USA) during or shortly after the donation (18).

166

167 We aimed to assess the impact of the new policy on the blood supply by comparing operational data
168 from the blood bank before, during and after the study period. We gathered data on whole blood
169 donations, donors and donations invitations from the blood bank database (eProgesa software
170 application; MAK-SYSTEM, Paris, France). Available donors were defined as not being deferred for
171 medical (iron-related or other), travel or lifestyle factors; new donors as showing up for the pre-
172 donation screening; and lapsed donors as deregistered or unresponsive to 5 subsequent invitations.
173 Demands for each year were based on hospital requests and converted to blood units.

174

175 *Data analyses*

176 Descriptive statistics are provided for the donors measured during measurement week 1. Using donors
177 measured during all four weeks, we conducted complete case analysis and used ordinary least squares
178 regression in case of continuous outcomes and logistic regression for binary outcomes. After diagnostic
179 tests of linearity and errors assumptions, a log base 10 transformation was applied to improve linearity
180 of ferritin. We conducted robust regression to analyse cognitive functioning, physical health, mental
181 health and fatigue, as the normality assumption for logistic regression was violated. Measurements
182 after implementation of the new policy were grouped in periods of 6 months and compared to the
183 control condition. The control condition was defined as no implementation or implementation less
184 than 6 months ago. Analyses were adjusted for age, weight and height, and stratified by sex and
185 menopausal status. Donor return analyses were adjusted for return being during a COVID-19 lockdown.
186 Null hypotheses are that there are no associations between implementation of the new policy and the
187 outcomes. A two-sided p-value of <0.05 is considered statistically significant and a Bonferroni
188 correction is applied. Statistical analyses were conducted using the R language and environment for
189 statistical computing (4.1.1) and the lme4 (1.1.33), car (3.1.2), lmtest (0.9.40), sandwich (3.0.2), olsrr
190 (0.5.3), and robustbase (0.95.1) packages. HTML files of the scripts and results produced in Quarto are
191 available through <https://github.com/Sanquin/FINDEM>.

192

193 *Deviations from protocol*

194 As the number of donors with low ferritin in the first implementation group was higher than
195 anticipated, further implementation was executed in smaller steps to mitigate the impact on the blood
196 supply (18). A fourth measurement week was added, a year after the third measurement week,
197 between November 23rd and 27th 2020). This fourth week enables evaluation of long-term results. We
198 furthermore deviated from the protocol by using ordinary least squares (OLS) regression instead of
199 linear mixed models. In the linear mixed models for analysis of the primary outcomes with random
200 effects for the donation centre clusters, the ICC ranged from 0.00 to 0.05; R^2 did not improve with
201 random effects; and residual variance exceeded the variance between clusters. This indicates that the
202 random effects of the donation centre clusters were of minimal importance and justifies the use of OLS
203 regression. We conducted sensitivity analyses for donor return, stratifying by ferritin level, reason for
204 deferral, and donation centre type. Lastly, we added a sixth element (impact on the blood supply) to
205 the research question.

206

207 **Results**

208 *Donor characteristics*

209 412,888 whole blood donors made 1,634,700 donations during the study period. We performed
210 measurements in samples of 37,621 donations by 36,099 donors (Figure 1). Overall, across the
211 randomization groups, baseline donor characteristics were well balanced and comparable with the
212 general donor population (Table 1, Table S1). Characteristics of the 7,573 participants in the
213 questionnaire are comparable to the baseline participants (Table S2).

214

215 *Ferritin, iron deficiency, Hb, and Hb deferral*

216 The prevalence of iron deficiency and Hb deferral decreased after implementation of the policy (Figure
217 2). Ferritin-guided donation intervals are associated with significantly higher ferritin and Hb levels and

218 less iron deficiency and Hb deferrals (Figure 3a). Compared to pre-implementation, the intervention
219 was associated with up to 0.24 ng/mL higher log₁₀ ferritin and 0.37 g/dL higher Hb at 36 months after
220 implementation in males (Figure 3a). In premenopausal and postmenopausal females, we also observe
221 positive, but smaller, associations with an increasing trend over time. Moreover, the odds ratio of 0.19
222 indicates that males are 81% less likely to be iron deficient at 36 months after implementation than
223 before the intervention (Figure 3a). In postmenopausal females, odds ratios also decrease over the
224 course of the trial, with iron deficiency being 87% less likely at 36 months after implementation
225 compared to pre-implementation (Figure 3a). Hb deferral in males was up to 77% less likely as time
226 since implementation increased, compared to pre-implementation. Similarly, in premenopausal
227 females, Hb deferral is up to 44% less likely at 30-35 months after implementation than at pre-
228 implementation (Figure 3a). In postmenopausal females, Hb deferral is up to 51% less likely at 36
229 months after implementation than at pre-implementation.

230

231 *Donor return*

232 After adjustment for return being during a COVID-19 lockdown, odds for donor return within six
233 months are lower at each time point after implementation compared to pre-implementation (Figure
234 3a). Generally, the negative association with donor return was stronger in males. At 36 months after
235 implementation, males were 42% less likely to return for donation (Figure 3a). For premenopausal and
236 postmenopausal females, we do not observe a consistent decrease in odds over time (Figure 3a). The
237 differences in odds between groups of ferritin levels, reasons for deferral and donation centre types
238 are mostly not statistically significant (Table S4-6).

239

240 *Iron deficiency-related symptoms*

241 There were no consistent significant patterns for pica, fatigue, cognitive functioning, the SF-36, and
242 warm glow after implementation of the new policy (Figure 3b). However, males and premenopausal

243 and postmenopausal females were 49%, 127%, and 127% more likely to report RLS at 24 months
244 after implementation than before implementation.

245

246 *Donor deferral, donation frequency and blood supply*

247 Over time after implementation of the policy, the number of donations decreased in line with
248 decreasing demand, but the number of invitations needed to obtain one donation increased (Table
249 2). The average donation frequency of donors decreased over the years and subsequently the
250 number of donors that donated increased. The number of available donors increased and the
251 proportion that donated fluctuated between 80 and 90% over the years. The number of
252 simultaneously unavailable donors stabilized at around 40,000 donors per year. While the percentage
253 of low ferritin deferrals increased as a result of the implemented policy, the percentage of low-Hb
254 deferrals decreased. The number of new donors at the blood bank was higher in 2019 and 2020 than
255 in other years, while the number of lapsed donors in 2019 was exceptionally low.

256

257 **Discussion**

258 This stepped-wedge cluster-randomised trial in whole blood donors shows that ferritin and Hb levels
259 are significantly higher and iron deficiency and Hb deferral significantly lower after the implementation
260 of ferritin-guided donation intervals compared to the prior standard of Hb monitoring only. Conversely,
261 we found that the odds of donor return within six months decreased substantially with this policy.
262 Most iron deficiency-related symptoms remained unaffected, except for an increase in reports of RLS.
263 The continuity of the blood supply was maintained, but additional efforts were required to account for
264 the decreased donor availability.

265

266 Ferritin-guided donation intervals were associated with significantly less iron deficiency and higher
267 ferritin and Hb levels compared to pre-implementation, consistent with findings from simulations

268 assessing the impact of ferritin testing (24). The weaker effects observed in premenopausal females
269 could be due to their already less frequent donations before the policy, driven by longer donation
270 intervals and more frequent low-Hb deferrals, providing more recovery time (25,26). Additionally,
271 because of more stable iron stores due to the healthy donor effect, combined with lower donation
272 frequency and ferritin levels in this group, may result in less pronounced improvements compared to
273 other groups (19,27). Our finding that the new policy is associated with significantly lower odds of
274 donor return supports previous findings on decreased return rates after deferral (26,28). The weaker
275 negative association with donor return in premenopausal females compared to other groups may
276 again be explained by their exposure to more frequent deferral through the old Hb monitoring policy.

277

278 The increased reporting of RLS seems surprising but may simply be a result of increased awareness
279 through the letter sent to donors upon implementation in their donation centre, in which restless legs
280 syndrome was specifically mentioned as a symptom of iron deficiency. Further investigation shows no
281 statistically significant correlation between RLS and ferritin levels. The lack of improvement we found
282 in self-reported iron deficiency-related symptoms may partially be due to the small number of
283 questionnaire participants before implementation. However, our findings align with previous
284 randomised placebo-controlled trials investigating iron repletion and self-reported donor health (29–
285 31). Moreover, the benevolence and warm glow that drive donors may overshadow negative health
286 consequences which stresses the need for more functional and objective measures of iron deficiency-
287 related symptoms like fatigue (23). Positive effects of the steady reduction in iron deficiency and Hb
288 deferral on self-reported iron deficiency-related symptoms may also be delayed and require longer
289 follow-up in future studies.

290

291 Given the results of this trial regarding donor health and the continued fulfilment of the hospital
292 demand during and after the implementation of ferritin-guided donation intervals, Sanquin Blood Bank
293 decided to keep the policy in place. Our findings do, however, raise important policy and practical

294 considerations. First, it provides policymakers with a monitoring option that requires no effort from
295 blood donors, may be more effective in protecting iron status than standard Hb monitoring practices,
296 and does not impose a risk of side effects compared to iron supplementation (12). However, the
297 decreasing donor availability due to decreasing odds of donor return and increased numbers of
298 deferred donors stress the need for intensified donor recruitment and retention efforts (25). This is
299 reflected in the blood bank practice, as more invitations are needed to obtain one donation. Moreover,
300 as donation frequencies decreased after implementation of the policy, more donors were needed to
301 reach donation demands. To increase donor availability, iron supplementation can be considered as
302 an alternative or additional strategy (10,24).

303

304 To our knowledge, this is the first randomised study that goes beyond the limitations of Hb monitoring
305 by evaluating the effectiveness of ferritin-guided donation intervals in improving Hb and ferritin levels,
306 donor return rates and decreasing iron deficiency, Hb deferrals, iron deficiency-related symptoms. One
307 of the major strengths is the stepped-wedge cluster randomised approach as it allows simultaneous
308 implementation and evaluation of a new policy. However, there are also limitations to this study. First,
309 the nature of the intervention poses a risk of overestimating the positive effect of ferritin-guided
310 donation intervals. Donors whose donation intervals are extended, may return less frequently,
311 potentially resulting in selection bias. The risk of overestimation is to some extent minimized as the
312 duration of the trial exceeds the length of extended donation intervals. There may also be undetected
313 delayed effects in this trial, because ferritin levels are measured at every fifth donation, and thus
314 individual donors may not be confronted with the policy immediately upon implementation in their
315 donation centre.

316

317 The FIND'EM study provides substantial evidence that ferritin-guided donation intervals increase Hb
318 and ferritin levels and thereby effectively prevent iron deficiency and Hb deferral, while efforts are
319 needed to mitigate effects on the blood supply. Future studies may investigate long-term effects on

320 donor health outcomes. Our results may help blood services worldwide to improve their donor iron
321 management policies in order to protect donors from developing iron deficiency.

322

323 **Declarations**

324 *Ethics approval and consent to participate*

325 Sanquin's Ethical Advisory Board has reviewed and approved the FIND'EM protocol. Only data from
326 donors who gave consent for their information and left-over material to be used for research
327 purposes at the health check were included in the study. Donors who completed questionnaires
328 provided informed consent for their questionnaire data to be matched with data from the donor
329 database.

330

331 **Declaration of interests**

332 The authors declare that they have no competing interests.

333

334 **Funding**

335 The current project is supported by the 'Product and Process Development Cellular Products Grant'
336 (PPOC18-15) granted to K. van den Hurk by the Research Programming Committee, Sanquin,
337 Amsterdam, The Netherlands.

338

339 **Authors' contributions**

340 KvdH designed the study. KvdH, MS, FP and FQ set up and coordinated data collection. AM, and SR
341 wrote the analysis plan and drafted the manuscript. AM, SR and FP conducted the analyses with
342 support from EH. The manuscript was critically reviewed and approved by all co-authors.

343 **Data sharing**

344 The study protocol of the FIND'EM trial including a statistical analysis plan was previously published.
345 Analysis code used to produce the results reported in this article are available online. Individual
346 participant data, after de-identification, that underlie the results reported in this article (text, tables,
347 figures, and appendices) are available to researchers from GDPR compliant institutions, after
348 provision of a methodologically sound and feasible proposal. Requests can be submitted to the
349 authors immediately following publication. A material transfer or research collaboration agreement
350 has to be agreed and signed with the researcher.

351 **Acknowledgements**

352 We would like to acknowledge all blood bank staff for their commitment to the implementation of
353 the policy and their efforts in collecting data for our study. We are thankful to all donors for their
354 contribution to the study and the blood supply.

References

1. Prinsze FJ, de Groot R, Timmer TC, Zalpuri S, van den Hurk K. Donation-induced iron depletion is significantly associated with low hemoglobin at subsequent donations. *Transfusion*. 2021;61(12):3344-52.
2. Boulton F. Evidence-based criteria for the care and selection of blood donors, with some comments on the relationship to blood supply, and emphasis on the management of donation-induced iron depletion. *Transfus Med*. 2008;18(1):13-27.
3. Newman B. Iron depletion by whole-blood donation harms menstruating females: the current whole-blood-collection paradigm needs to be changed. *Transfusion*. 2006;46(10):1667-81.
4. Brittenham GM. Iron balance in the red blood cell donor. *Dev Biol (Basel)*. 2005;120:77-82.
5. Vinkenoog M, van den Hurk K, van Kraaij M, van Leeuwen M, Janssen MP. First results of a ferritin-based blood donor deferral policy in the Netherlands. *Transfusion*. 60(8):1785-92.
6. Boulton F. Managing donors and iron deficiency. *Vox Sang*. 2004;87 Suppl 2:22-4.
7. Schotten N, Pasker-de Jong PC, Moretti D, Zimmermann MB, Geurts-Moespot AJ, Swinkels DW, e.a. The donation interval of 56 days requires extension to 180 days for whole blood donors to recover from changes in iron metabolism. *Blood*. 2016;128(17):2185-8.
8. Alvarez-Ossorio, Kirchner, Klüter, Schlenke. Low ferritin levels indicate the need for iron supplementation: strategy to minimize iron-depletion in regular blood donors. *Transfusion Medicine*. 1 juni 2000;10(2):107-12.
9. Pratt JJ, Khan KS. Non-anaemic iron deficiency - a disease looking for recognition of diagnosis: a systematic review. *Eur J Haematol*. 2016;96(6):618-28.
10. Pasricha SR, Low M, Thompson J, Farrell A, De-Regil LM. Iron Supplementation Benefits Physical Performance in Women of Reproductive Age: A Systematic Review and Meta-Analysis. *The Journal of Nutrition*. juni 2014;144(6):906-14.
11. Krayenbuehl PA, Battegay E, Breymann C, Furrer J, Schulthess G. Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. *Blood*. 2011;118(12):3222-7.
12. Smith GA, Fisher SA, Doree C, Di Angelantonio E, Roberts DJ. Oral or parenteral iron supplementation to reduce deferral, iron deficiency and/or anaemia in blood donors. *Cochrane Database Syst Rev*. 2014;(7):CD009532.
13. Baart AM, van den Hurk K, de Kort WL. Minimum donation intervals should be reconsidered to decrease low hemoglobin deferral in whole blood donors: an observational study. *Transfusion*. 2015;55(11):2641-4.
14. Di Angelantonio E, Thompson SG, Kaptoge S, Moore C, Walker M, Armitage J, e.a. Efficiency and safety of varying the frequency of whole blood donation (INTERVAL): a randomised trial of 45 000 donors. *Lancet*. 2017;390(10110):2360-71.
15. Spencer B. Blood donor iron status: are we bleeding them dry? *Curr Opin Hematol*. 2013;20(6):533-9.

16. Cable RG, Brambilla D, Glynn SA, Kleinman S, Mast AE, Spencer BR, e.a. Effect of iron supplementation on iron stores and total body iron after whole blood donation. *Transfusion*. 2016;56(8):2005-12.
17. Cable RG, Glynn SA, Kiss JE, Mast AE, Steele WR, Murphy EL, e.a. Iron deficiency in blood donors: the REDS-II Donor Iron Status Evaluation (RISE) study. *Transfusion*. 2012;52(4):702-11.
18. Sweegers MG, Zalpuri S, Quee FA, Huis in 't Veld EMJ, Prinsze FJ, Hoogendijk EO, e.a. Ferritin measurement IN Donors—Effectiveness of iron Monitoring to diminish iron deficiency and low haemoglobin in whole blood donors (FIND'EM): study protocol for a stepped wedge cluster randomised trial. *Trials*. 2020;21(1):823.
19. Moazzen S, Sweegers MG, Janssen M, Hogema BM, Hoekstra T, Van Den Hurk K. Ferritin Trajectories over Repeated Whole Blood Donations: Results from the FIND+ Study. *JCM*. 21 juni 2022;11(13):3581.
20. Ware Jr. JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992;30(6):473-83.
21. Vercoulen JHMM; SCMA; FJFM; GJMD; van der MJWM; BG. de Checklist Individual Strength (CIS). *Gedragstherapie*. 1999;32:131-6.
22. Van den Hurk K, Peffer K, Habets K, Atsma F, Pasker-de Jong PCM, Van Noord PAH, e.a. Blood donors' physical characteristics are associated with pre- and post-donation symptoms - Donor InSight. *Blood Transfus*. 2017;15(5):405-12.
23. Ferguson E, Atsma F, de Kort W, Veldhuizen I. Exploring the pattern of blood donor beliefs in first-time, novice, and experienced donors: differentiating reluctant altruism, pure altruism, impure altruism, and warm glow. *Transfusion*. 2012;52(2):343-55.
24. Richard P, Fillet A, Malard L, Leclerc C, Chanut C, Woimant G, e.a. Impact of donor ferritin testing on iron deficiency prevention and blood availability in France: A cohort simulation study. *Vox Sanguinis*. januari 2023;118(1):24-32.
25. Spekman MLC, Ramondt S, Sweegers MG. Whole blood donor behavior and availability after deferral: Consequences of a new ferritin monitoring policy. *Transfusion*. april 2021;61(4):1112-21.
26. Spekman MLC, Tilburg TG, Merz E. Do deferred donors continue their donations? A large-scale register study on whole blood donor return in the Netherlands. *Transfusion*. december 2019;59(12):3657-65.
27. Atsma F, Veldhuizen I, Verbeek A, de Kort W, de Vegt F. Healthy donor effect: its magnitude in health research among blood donors. *Transfusion*. 2011;51(8):1820-8.
28. Custer B, Schlumpf KS, Wright D, Simon TL, Wilkinson S, Ness PM, e.a. Donor return after temporary deferral. *Transfusion*. 2011;51(6):1188-96.
29. Hod EA, Brittenham GM, Bitan ZC, Feit Y, Gaelen JI, La Carpia F, e.a. A randomised trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being. *Blood*. 22 december 2022;140(25):2730-9.

30. Waldvogel S, Pedrazzini B, Vaucher P, Bize R, Cornuz J, Tissot JD, e.a. Clinical evaluation of iron treatment efficiency among non-anemic but iron-deficient female blood donors: a randomised controlled trial. *BMC Med.* 2012;10:8.
31. Keller P, von Känel R, Hincapié CA, da Costa BR, Jüni P, Erlanger TE, e.a. The effects of intravenous iron supplementation on fatigue and general health in non-anemic blood donors with iron deficiency: a randomised placebo-controlled superiority trial. *Sci Rep.* 26 augustus 2020;10(1):14219.

Table 1. Donor characteristics in measurement week 1, where group 1 had just implemented the new policy and groups 2, 3, and 4 were considered controls.

	Group 1 ¹	Group 2	Group 3	Group 4	Overall
Pre-menopausal, female donors	N = 688	N = 590	N = 634	N = 465	N = 2,377
New donors, N (%)	167 (24.3)	109 (18.5)	131 (20.7)	86 (18.5)	493 (20.7)
Age (years), median [IQR]	25.0 [21.0, 33.0]	26.0 [21.0-34.0]	26.0 [22.0-33.8]	25.0 [21.0-31.0]	25.0 [21.0-33.0]
Height (cm), mean (SD)	171 (6.4)*	171 (6.9)	171 (6.3)*	171 (6.4)	171 (6.5)*
Weight (kg), mean (SD)	71.0 (12.2)*	71.0 (12.4)	71.4 (11.9)	70.8 (12.1)	71.1 (12.2)*
Hemoglobin, median [IQR], g/dL	13.4 [12.7-12.4]	13.4 [12.9-14.0]	13.5 [12.9-14.0]	13.4 [12.9-14.0]	13.4 [12.9-14.0]
Low hemoglobin deferral (<12.5 g/dL), N (%)	64 (9.3)	34 (5.8)	46 (7.3)	43 (9.2)	187 (7.9)
Ferritin, median [IQR], ng/mL	26.2 [13.3-46.2]**	24.4 [12.1-46.7]**	24.7 [12.7-45.5]**	23.7 [10.3-40.3]**	25.1 [12.3-45.4]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	161 (23.4)**	159 (26.9)**	173 (27.3)**	130 (28.0)**	623 (26.2)**
Total number of whole blood donations, median [IQR]	2.0 [1.0-7.0]	3.0 [1.0-9.0]	4.0 [1.0-10.0]	3.0 [1.0-9.0]	3.0 [1.0-9.0]
Number of whole blood donations in the past 2 years, median [IQR]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	2.0 [1.0-4.0]	3.0 [1.0-4.0]	2.0 [1.0-4.0]
Donor return within 6 months of first allowed date, N (%)	478 (66.5)	383 (64.9)	436 (68.8)	323 (69.5)	1,620 (68.2)
Post-menopausal, female donors	N = 388	N = 379	N = 387	N = 308	N = 1,462
New donors, N (%)	11 (2.8)	7 (1.8)	13 (3.4)	2 (0.6)	33 (2.3)
Age (years), median [IQR]	55.0 [49.0-60.0]	55.0 [50.0-61.0]	56.0 [49.0-60.0]	55.0 [49.8-62.0]	55.0 [50.0-61.0]
Height (cm), mean (SD)	170 (5.9)	169 (6.1)	170 (6.2)	170 (5.9)	170 (6.0)
Weight (kg), mean (SD)	74.5 (11.3)	73.4 (12.3)	73.9 (12.4)	73.3 (11.6)	73.8 (11.9)
Hemoglobin, median [IQR], g/dL	13.9 [13.1-14.5]	13.5 [13.1-14.5]	13.7 [13.1-14.3]	13.5 [13.1-14.3]	13.7 [13.1-14.3]
Low hemoglobin deferral (<12.5 g/dL), N (%)	19 (4.9)	19 (5.0)	21 (5.4)	11 (3.6)	70 (4.8)
Ferritin, median [IQR], ng/mL	27.4 [13.5-44.0]***	28.3 [14.0-45.8]**	25.7 [13.2-45.0]**	26.7 [15.0-43.6]**	27.4 [13.7-45.0]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	85 (21.9)***	87 (23.0)**	95 (24.5)**	64 (20.8)**	331 (22.6)**
Total number of whole blood donations, median [IQR]	29.0 [11.0-50.0]	26.0 [12.0-42.0]	29.0 [12.0-46.0]	29.0 [12.0-47.0]	28.0 [12.0-46.0]
Number of whole blood donations in the past 2 years, median [IQR]	5.0 [3.0-5.0]	4.0 [3.0-5.0]	5.0 [3.0-6.0]	5.0 [3.0-5.0]	5.0 [3.0-6.0]
Donor return within 6 months of first allowed date, N (%)	297 (76.5)	292 (77.0)	310 (80.1)	237 (76.9)	1,136 (77.7)
Male donors	N = 1075	N = 1061	N = 1007	N = 870	N = 4,013
New donors, N (%)	58 (5.4)	63 (5.9)	46 (4.6)	47 (5.4)	214 (5.3)
Age (years), median [IQR]	48.0 [32.0-58.5]	51.0 [35.0-60.0]	49.0 [32.5-58.0]	49.0 [31.0-59.0]	49.0 [32.0-59.0]
Height (cm), mean (SD)	184 (7.1)	183 (7.2)	183 (6.9)	183 (7.5)	183 (7.2)
Weight (kg), mean (SD)	86.5 (12.1)	85.8 (12.2)	85.4 (12.0)	85.4 (11.9)*	85.8 (12.1)
Hemoglobin, median [IQR], g/dL	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.6]	14.8 [14.2-15.5]	14.8 [14.2-15.6]
Low hemoglobin deferral (<13.5 g/dL), N (%)	42 (3.9)	27 (2.5)	34 (3.4)	27 (3.1)	130 (3.2)
Ferritin, median [IQR], ng/mL	25.3 [12.3-54.9]**	25.9 [13.2-55.3]**	24.8 [12.4-50.0]**	24.5 [11.6-54.8]**	25.2 [12.4-53.2]**
Iron deficiency (ferritin < 15 ng/mL), N (%)	280 (26.0)**	273 (25.7)**	272 (27.0)**	243 (27.9)**	1,068 (26.6)**
Total number of whole blood donations, median [IQR]	30.0 [7.0-68.0]	39.0 [8.0-71.0]	32.0 [8.0-64.0]	31.5 [7.0-70.0]	32.0 [7.0-68.0]
Number of whole blood donations in the past 2 years, median [IQR]	6.0 [4.0-9.0]	6.0 [4.0-9.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]	6.0 [4.0-8.0]
Donor return within 6 months of first allowed date, N (%)	924 (86.0)	905 (85.3)	870 (86.4)	738 (84.8)	3,437 (85.6)

¹Randomly assigned clusters of donation centres (Group 1-3: 8 clusters, group 4: 5 clusters)

Missing: * < 10%, ** 10-20%, *** > 20%

Table 2. Blood bank statistics per calendar year to describe impact of new policy on blood supply in the Netherlands. Ferritin-guided donation intervals were implemented, in a step-wise manner, in November 2017. Hence, there is no data on extended intervals due to low ferritin in 2016. In November 2019 implementation was completed and in November 2020 the study was completed. All statistics are presented for whole blood donations only.

	2016	2017	2018	2019	2020	2021	2022
Hospital demand (in donation units)	418,491	407,215	406,199	407,460	402,578	400,757	392,805
Donations	421,019	410,956	412,266	412,479	411,021	406,845	393,633
Donors	234,821	234,224	237,985	248,911	278,863	262,956	260,033
Average donation frequency per donor	1.79	1.75	1.73	1.66	1.47	1.55	1.51
Average invitations per donation	2.83	2.95	3.03	3.12	3.19	3.41	3.59
Extended donation intervals ¹							
Number of donations	-	1,979	19,044	45,829	60,938	63,695	66,635
Percentage of donations	-	0.48	4.62	11.11	14.83	15.66	16.93
Unique donors	-	1,973	17,441	38,961	53,841	51,140	45,696
Hb deferral							
Number of donations	38,143	39,083	37,733	30,411	20,479	21,589	21,494
Percentage of donations	9.06	9.51	9.15	7.37	4.98	5.31	5.46
Unique donors	32,008	32,844	31,539	26,222	20,599	16,813	17,820
Available donors ²	286,597	273,379	283,550	305,225	312,930	308,751	322,637
Unavailable donors due to low ferritin	-	1,973	14,435	32,585	42,709	39,570	38,901
Available donors invited to donate (%)	81.93	85.68	83.93	81.55	80.11	85.17	80.60
New donors	50,107	44,362	58,419	60,121	71,983	54,194	53,194
Lapsed donors	49,066	51,579	42,782	26,571	47,918	55,341	29,982

¹ Due to low ferritin (including both <15 ng/mL and 15-30 ng/mL)

² On December 31




Figure 1. Flow chart of stepped-wedge cluster randomized trial and intervention roll out by randomization group






Figure 2. Percentage of low Hb and ferritin deferral per sex in controls and at six timepoints post-intervention.

A Associations of implementation of ferritin-guided donation intervals with primary study outcomes



Ferritin: log10 ng/mL; Hb: g/dL; Iron deficiency: ferritin < 15 ng/mL; Hb deferral: males < 13.5 g/dL, females < 12.5 g/dL; Return: within 6 months of first allowed date. Reference group: no implementation and 0-5 months since implementation. All analyses are adjusted for age, height and weight. Return is additionally adjusted for whether return would be during first COVID lockdown (March-May 2020). Statistical significance: Bonferroni correction applied to adjust for multiple testing (0.05/6).

B Associations of implementation of ferritin-guided donation intervals with secondary study outcomes



Statistical significance: Bonferroni correction applied to adjust for multiple testing (0.05/6). Cognitive functioning: higher score indicates worse result. Physical & mental health: higher score indicates better result.

Figure 3. Results of regression analyses for iron-related outcomes, donor return and iron-deficiency related symptoms. Corresponding coefficients, confidence intervals and p-values are displayed in Table S3.